Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With Paclitaxel and Cisplatin as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: a Randomized, Double-blind, Multicenter, Phase 3 Study (ORIENT-15)

Trial Profile

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With Paclitaxel and Cisplatin as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: a Randomized, Double-blind, Multicenter, Phase 3 Study (ORIENT-15)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2019

At a glance

  • Drugs Sintilimab (Primary) ; Cisplatin; Paclitaxel
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ORIENT-15
  • Sponsors Innovent Biologics
  • Most Recent Events

    • 01 Jan 2019 According to an Innovent Biologics media release, the first patient has been dosed in this phase III trial.
    • 01 Jan 2019 Status changed from not yet recruiting to recruiting, according to an Innovent Biologics media release.
    • 27 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top